Home Featured

Featured

Random

The Need for an International Psychedelic Religious Survey

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

Psychedelic Capitalism and Other Myths: Is the Joke On Us?

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

Entheon Biomedical Corp. Provides Corporate Update

Stephen Bardin to Join atai Life Sciences as CFO Designate

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1...

PT292 – Sam Gandy – Vital Psychedelic Conversations

Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Free Webinar — Psychedelics for Veterans: The Battle for a Better...

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder...

Wesana Health Highlights Recent Appointments to Board of Directors

PTSF67 – Psilocybin, Power, and Patents

12 3...176 Page 1 of 176

Psychedelics Weekly – Genetic Memory, “The Psychedelic Renaissance,” and Harm Reduction...

Webinar: Psychedelic Integration and Depth Relational Process

Abuse Potential: Considerations for Rescheduling MDMA and Psychedelics

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.